| Title |
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2013
|
| DOI | 10.1007/s00262-013-1418-6 |
| Pubmed ID | |
| Authors |
Anna Maria Di Giacomo, Luana Calabrò, Riccardo Danielli, Ester Fonsatti, Erica Bertocci, Isabella Pesce, Carolina Fazio, Ornella Cutaia, Diana Giannarelli, Clelia Miracco, Maurizio Biagioli, Maresa Altomonte, Michele Maio |
| Abstract |
Ipilimumab can result in durable clinical responses among patients with advanced melanoma. However, no predictive marker of clinical activity has yet been identified. We provide preliminary data describing the correlation between immunological parameters and response/survival among patients with advanced melanoma who received ipilimumab 10 mg/kg in an expanded access programme. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 1% |
| Australia | 1 | 1% |
| Canada | 1 | 1% |
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 93 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 24% |
| Student > Ph. D. Student | 12 | 12% |
| Student > Bachelor | 12 | 12% |
| Student > Master | 7 | 7% |
| Other | 7 | 7% |
| Other | 15 | 15% |
| Unknown | 21 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 43% |
| Agricultural and Biological Sciences | 14 | 14% |
| Immunology and Microbiology | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Computer Science | 2 | 2% |
| Other | 6 | 6% |
| Unknown | 25 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2022.
All research outputs
#2,539,213
of 23,479,361 outputs
Outputs from Cancer Immunology, Immunotherapy
#134
of 2,932 outputs
Outputs of similar age
#21,849
of 199,318 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#3
of 21 outputs
Altmetric has tracked 23,479,361 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,932 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,318 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.